Pricey blockbuster GLP-1s are costing users — and most of the rest of us, too

Health

Pricey blockbuster GLP-1s are costing users — and most of the rest of us, too

Health insurers are passing along cost for coverage in form of higher rates across the board, policy researcher says

Sy Boles

Harvard Staff Writer

February 13, 2026 7 min read

The popularity of pricey GLP-1 drugs has hit the budgets of users — and just about everyone else.

In the U.S....